



Allergy Therapeutics plc
("Allergy Therapeutics" or the "Group")

Result of Annual General Meeting

16 December 2024 Allergy Therapeutics plc (AIM:AGY), the fully integrated specialty pharmaceutical group specialising in allergy vaccines, announces that all resolutions proposed at the 2024 Annual General Meeting ("AGM") held today were duly passed by shareholders on a show of hands.

Resolutions 1 to 13 (inclusive) were proposed as ordinary resolutions and resolutions 14 to 16 (inclusive) were proposed as special resolutions. The results of the proxy votes received ahead of the meeting are outlined in the table below.

Resolution	For:	%age	Against:	%age	Total Votes Cast	% of ISC	Withheld
1. Approval of 2024 Accounts	4,452,448,269	99.99	3,624	0.01	4,452,453,003	93.41	1,110
2. Approval of Directors' Remuneration Report	4,451,072,636	99.97	1,379,257	0.03	4,452,453,003	93.41	1,110
3. Approval of Directors' Remuneration Policy	4,438,375,536	99.68	14,075,557	0.32	4,452,453,003	93.41	1,910
4. To elect Dr. Shaun Furlong as a Director	4,450,412,573	99.99	33,283	0.01	4,452,453,003	93.41	2,007,147
5. To elect David Ball as a Director	4,450,411,773	99.99	33,283	0.01	4,452,453,003	93.41	2,007,947
6. To re-elect Anthony Parker as a Director	4,436,433,902	99.69	14,011,154	0.31	4,452,453,003	93.41	2,007,947
7. To re-elect Zheqing (Simon) Shen as a Director	4,436,433,902	99.69	14,011,154	0.31	4,452,453,003	93.41	2,007,947
8. To re-elect Peter Jensen O.B.E. as a Director	4,436,433,902	99.69	14,011,154	0.31	4,452,453,003	93.41	2,007,947
9. To re-appoint BDO LLP as auditors of the Company	4,451,995,528	99.99	3,624	0.01	4,452,453,003	93.41	453,851
10. To authorise the Directors to agree the Auditors remuneration	4,452,434,231	99.99	11,625	0.01	4,452,453,003	93.41	7,147
11. To approve the form of contract and authorise the off-market purchase of deferred shares	4,452,433,431	99.99	11,625	0.01	4,452,453,003	93.41	7,947
12. To authorise the Directors to finalise and implement arrangements for							

the grant of the special, out of cycle, long term incentive awards to the Company's senior executive team and additional option awards to the Company's employees.	4,436,556,360	99.69	13,895,533	0.31	4,452,453,003	93.41	2,001,110
13. To authorise the Directors to allot the unissued share capital up to a specific amount (s.551)	4,452,337,990	99.99	15,655	0.01	4,452,453,003	93.41	99,358
14. Special Resolution: To authorise the Directors to allot equity securities for cash without first being required to offer such shares to existing shareholders for a period expiring at the conclusion of the next annual general meeting of the Company or 16 March 2026, whichever occurs first.	4,438,461,319	99.69	13,892,326	0.31	4,452,453,003	93.41	99,358
15. Special Resolution: To authorise the Directors to allot equity securities and/or sell treasury shares for cash without first being required to offer such securities to existing shareholders.	4,438,461,319	99.69	13,892,326	0.31	4,452,453,003	93.41	99,358
16. Special Resolution: To amend the Articles of Association.	4,450,427,300	99.99	17,756	0.01	4,452,453,003	93.41	2,007,947

- ENDS -

Allergy Therapeutics

Manuel Llobet, Chief Executive Officer
 Shaun Furlong, Chief Financial Officer
 +44 (0)1903 845 820

Cavendish Capital Markets Limited (Nominated Adviser and Broker)

Geoff Nash /Giles Balleny/ Seamus Flicker / Rory Sale
 Nigel Birks - Life Science Specialist Sales
 Tamar Cranford Smith - Sales
 +44 (0)20 7220 0500

ICR Healthcare

Mary-Jane Elliott / David Daley / Davide Salvi
 +44 (0)20 3709 5700
allergytherapeutics@icrhealthcare.com

Notes for editors:

About Allergy Therapeutics

Allergy Therapeutics is an international commercial biotechnology company, headquartered in the UK, focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third-party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development includes vaccines for grass, tree, house dust mite and peanut. For more information, please see www.allergytherapeutics.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@lseg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

RAGFFUFIMELSEEE